ABL1 (Y245F)
Sign in to save this workspaceABL1 · Variant type: point · HGVS: p.Y245F
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Vandetanib | 93.9% | 6.1% | 95.74 |
| 2 | Repotrectinib | 88.3% | 11.7% | 84.21 |
| 3 | Canertinib | 88.1% | 11.9% | 96.49 |
| 4 | Pacritinib | 88.0% | 12.0% | 88.64 |
| 5 | Tivozanib | 85.8% | 14.2% | 92.42 |
| 6 | Erdafitinib | 83.3% | 16.7% | 95.71 |
| 7 | Ripretinib | 80.7% | 19.3% | 92.95 |
| 8 | Fedratinib | 76.0% | 24.0% | 96.21 |
| 9 | Erlotinib | 68.2% | 31.8% | 99.75 |
| 10 | Sunitinib | 61.4% | 38.6% | 91.73 |
| 11 | Selpercatinib | 60.6% | 39.4% | 96.72 |
| 12 | Avapritinib | 59.3% | 40.7% | 97.73 |
| 13 | Entrectinib | 55.6% | 44.4% | 93.69 |
| 14 | Pralsetinib | 48.2% | 51.8% | 93.43 |
| 15 | Gilteritinib | 42.8% | 57.3% | 88.97 |
| 16 | Defactinib | 32.1% | 67.9% | 92.68 |
| 17 | Neratinib | 28.6% | 71.4% | 93.18 |
| 18 | Mobocertinib | 27.8% | 72.2% | 97.22 |
| 19 | Deucravacitinib | 26.3% | 73.7% | 98.99 |
| 20 | Alpelisib | 25.4% | 74.6% | 97.22 |
| 21 | Infigratinib | 22.3% | 77.7% | 98.24 |
| 22 | Umbralisib | 19.6% | 80.4% | 98.74 |
| 23 | Upadacitinib | 17.9% | 82.1% | 97.98 |
| 24 | Sorafenib | 16.6% | 83.4% | 96.72 |
| 25 | Apatinib | 15.7% | 84.3% | 97.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Vandetanib | 93.9% | 95.7% | -1.8% |
| Repotrectinib | 88.3% | 93.6% | -5.3% |
| Canertinib | 88.1% | 91.6% | -3.5% |
| Pacritinib | 88.0% | 92.0% | -4.0% |
| Tivozanib | 85.8% | 95.8% | -10.0% |
| Erdafitinib | 83.3% | 90.9% | -7.6% |
| Ripretinib | 80.7% | 82.9% | -2.2% |
| Fedratinib | 76.0% | 82.7% | -6.6% |
| Erlotinib | 68.2% | — | — |
| Sunitinib | 61.4% | — | — |
| Selpercatinib | 60.6% | — | — |
| Avapritinib | 59.3% | — | — |
| Entrectinib | 55.6% | — | — |
| Pralsetinib | 48.2% | — | — |
| Gilteritinib | 42.8% | — | — |
| Defactinib | 32.1% | — | — |
| Neratinib | 28.6% | — | — |
| Mobocertinib | 27.8% | — | — |
| Deucravacitinib | 26.3% | — | — |
| Alpelisib | 25.4% | — | — |
| Infigratinib | 22.3% | — | — |
| Umbralisib | 19.6% | — | — |
| Upadacitinib | 17.9% | — | — |
| Sorafenib | 16.6% | — | — |
| Apatinib | 15.7% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.9ms